EQS-News: Biotest AG: Biotest receives 'Innovation Champion of Sustainability' award

PRESS RELEASE

Biotest receives "Innovation Champion of Sustainability" award

• Biotest achieves very good 5^th place in sustainability analysis by F.A.Z.-Institute
• With its GoFuture sustainability initiative, Biotest aims to grow in line with social and ecological requirements.

Dreieich, 19 January 2023. The renowned F.A.Z. Institute, together with the Institute for Management and Economic Research (IMWF), has named Biotest AG the "Innovation Champion of Sustainability". In a Germany-wide study business experts examined and evaluated a total of 10,000 companies on the topics of innovation, research and development as well as ecological, social and economic sustainability on the Internet. Among the pharmaceutical companies rated as sustainable in the study, Biotest achieved 5^th place.

"The efficient use of resources is in our DNA. We are very pleased that our path to a sustainable future is also being noticed," emphasises Dirk Neumüller, Chief Sustainability Officer at Biotest AG. "The award is a recognition of the commitment of the employees at Biotest and at the same time a motivation to further advance the topic of sustainability in the company."

To promote sustainability awareness at Biotest, the GoFuture campaign was launched. With it, Biotest is pursuing a vision that is committed to a sustainable future. To this end, the company is constantly expanding its sustainability efforts and, among other things, is focusing on targeted measures for a better climate balance - with the goal of complete climate neutrality by 2035. For more information on GoFuture, please visit the homepage at:

https://www.biotest.com/de/en/company/sustainability-/gofuture.cfm

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,200 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact

Dr Monika Buttkereit

Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller

Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities ID No. 522720; ISIN DE0005227201

Preference shares: securities ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.